IMPACT OF EGFR MUTATION ON PROGNOSIS OF STAGE IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER NSCLC: A RETROSPECTIVE ANALYSIS

: Background: Patients with activating somatic mutations in the Epidermal Growth Factor Receptor (EGFR) have better prognosis when treated with Tyrosine Kinase Inhibitors (TKI) as the standard treatment of care in advanced stage NSCLC. Aim of the work: To study the impact of EGFR mutation on prognosis of advanced stage non-squamous NSCLC. Patients and Methods: This is a cross-sectional, retrospective-cohort study of stage IV non squamous non-small cell lung cancer (January 2019-june2021). This study was done at both Clinical Oncology and Nuclear Medicine department Ain Shams university Hospital and Nasser Institute Cancer Centre for research and treatment (NICC) EGFR mutation status, treatment, progression free survival, overall survival and response rate were evaluated. Primary end point: progression free survival of stage IV NSCLC with wild type and mutant EGFR. Secondary end point: overall survival of stage IV NSCLC with EGFR mutation and wild type, response rate to treatment. Results: From the 87 patients which performed screening for EGFR mutations, 20 (23%) had mutations, while 64 (73%) had wild type EGFR. The